Karyopharm Grants Inducement Equity to New Hires

The restricted stock units follow a three-year vesting schedule. One-third of the shares will vest on each of the three consecutive anniversaries following the grant date. This arrangement remains contingent upon the recipients maintaining their status as service providers or employees at Karyopharm through each designated vesting date.

Karyopharm, which focuses on nuclear export inhibition for cancer treatment, continues to utilize its 2022 Inducement Stock Incentive Plan to attract talent. The company currently markets XPOVIO, a first-in-class exportin 1 inhibitor, for patients with relapsed or refractory multiple myeloma. Beyond its existing commercial portfolio, the firm is researching the application of selinexor and next-generation compounds like eltanexor for various hematological malignancies and myeloproliferative neoplasms.